Case Study 1 — Alma, Seven Years On: The Immunotherapy Decision

The Ortiz-Lindqvist household is an illustrative composite carried through this book — Marisol Ortiz, Erik Lindqvist, Alma (7) and Nico (13). ⚠️ The clinical facts about oral immunotherapy, the desensitization/tolerance distinction and the trade-offs are real; the family is constructed. ⚠️ Nothing here is a treatment recommendation. This is a decision made with a specialist.**

Setup

Alma reacted to peanut at eleven months old, at her grandmother's house, from a smear of satay sauce on a spoon.

Hives, vomiting, and then a hoarse cry. ⚠️ Her grandmother, who had never seen it before, gave her antihistamine and phoned Marisol.

Marisol drove home, saw her, and called an ambulance. Adrenaline was given in the ambulance, approximately forty minutes after the reaction started.

⚠️ Alma was fine. And that forty minutes is the reason this family does everything the way it does.

She is seven now. Confirmed IgE-mediated peanut allergy — history plus specific IgE plus component testing. ⚠️ No further reactions in six years, because the household has been immaculate.

What immaculate has cost

⚠️ This is the part rarely accounted for.

⚠️ And Nico, who is thirteen, said something at the assessment that his mother had not heard before:

"I stopped bringing friends round. It's easier."

Why they were considering immunotherapy

Not to cure it. ⚠️ Marisol had read enough to know that wasn't on offer.

"She's going to be a teenager. I've read what happens to teenagers."

⚠️ She is right, and §28.3 says so: adolescence and young adulthood are the highest-risk period — devices left behind, eating out, alcohol, and not wanting to be the person who makes a fuss.

What they wanted was ⚠️ protection against an accidental exposure, at the point when Alma's life would stop being supervised.

The consultation

⚠️ The specialist's first move was to correct a word.

"I want to be clear about what this does, because families arrive with the wrong idea and it causes real problems later.

⚠️ "This is DESENSITIZATION, not tolerance. It raises the amount she can be exposed to before she reacts, for as long as she keeps taking it daily. It does not cure the allergy. If she stops, the protection goes.

"She will still avoid peanut. She will still carry adrenaline. She will still read labels."

Marisol:

"So what does it actually buy us?"

⚠️ "If she eats something with traces in it by accident — which will happen, because she'll be nineteen and in a kebab shop at 2am — she is much more likely to have a mild reaction than a severe one. That's the thing it buys."

⚠️ Then the other side, unprompted:

⚠️ "Reactions during treatment are common. Some are significant. Some analyses find more anaphylaxis during the treatment period than with avoidance. A minority develop eosinophilic oesophagitis, which means stopping. And it's a daily dose, at a fixed time, for years — with a child who will at some point not want to."

💡 Aha moment. ⚠️ The trade is not "risk versus safety." It is DISTRIBUTED risk versus CONCENTRATED risk.

Avoidance means low day-to-day risk and a small chance of a severe, unsupervised event. Immunotherapy means a higher rate of managed reactions now, in exchange for a less severe unsupervised event later.

⚠️ Which is a values question, not a clinical one, and the family is the right decision-maker. A specialist who presents it as obviously correct has taken that decision away from them.

What they decided, and how

⚠️ They took six weeks, and they asked Alma.

She is seven, and she was not the decision-maker — but the specialist made a point of asking her directly what she wanted, and what worried her.

⚠️ Her two questions:

"Will it hurt?" "Will I be able to go to Priya's house?"

⚠️ The second one is the whole thing. She had understood the goal better than anyone had explained it to her.

They said yes.

Eighteen months on

⚠️ The clinical change is a raised threshold. Four of the seven rows that changed are social.

What Marisol said at the review:

"I thought it would feel like it was over. It doesn't. It feels like she's got a bigger margin — and I sleep, which I didn't."

Analysis

1. ⚠️ Forty minutes to adrenaline at eleven months is the origin of everything. The family's vigilance is proportionate to a real event, not to anxiety.

2. ⚠️ The costs of immaculate avoidance are mostly social and mostly uncounted — parties, sleepovers, restaurants, a sibling not bringing friends home, and a mother who hasn't eaten unchecked in six years.

3. ⚠️ The specialist corrected the word first. Desensitization, not tolerance. A family told "this will fix it" is being set up for a misunderstanding that surfaces in a supermarket aisle three years later.

4. ⚠️ The trade is distributed versus concentrated risk — more managed reactions now, less severe unsupervised risk later. A values decision, and the family is the right decision-maker.

5. The adverse events were real — several reactions during build-up, one requiring adrenaline, a six-week hold. ⚠️ This is the expected course, not a complication of a badly-run programme.

6. ⚠️ Alma's own question was the right one. "Will I be able to go to Priya's house?" A seven-year-old had located the actual outcome faster than the adults had articulated it.

7. ⚠️ Nothing about avoidance changed. Devices, labels, no peanut. The allergy is still there.

8. And the outcome that mattered most to the household wasn't the threshold. ⚠️ It was four sleepovers and a thirteen-year-old bringing friends home.

Discussion Questions

1. ⚠️ Forty minutes to adrenaline, with an antihistamine given first. Who failed here — and what would have prevented it? Design the intervention.

2. The specialist described the downside unprompted. ⚠️ How much of an intervention's downside should be volunteered versus disclosed on request? Does your answer change when the patient is a child?

3. ⚠️ Distributed versus concentrated risk. Find two other decisions in this book with the same structure. Do people reason about them consistently?

4. Alma was asked, at seven, but did not decide. ⚠️ At what age should she decide? What would have to be true?

5. ⚠️ Nico's "I stopped bringing friends round" had never been said aloud. How should the effects on siblings be surfaced? Whose job is it?

6. ⚠️ Four of the seven changed rows are social, not clinical. Should social outcomes be recorded in immunotherapy trials? What would that change about how the intervention is evaluated?

Your Turn

⚠️ For anyone with, or caring for someone with, an IgE-mediated food allergy.

Step 1 — The device audit. Today.

• [ ] ⚠️ Two devices, carried, wherever the person goes
• [ ] In date — check the expiry now
• [ ] ⚠️ Everyone who cares for them knows where they are AND how to use one
• [ ] A written plan exists — school, nursery, grandparents, sports club
• [ ] ⚠️ The person themselves knows, at an age-appropriate level

⚠️ A device at home is a device you don't have.

Step 2 — The hesitation rehearsal. ⚠️ Say it out loud:

Airway, breathing or circulation — or two or more systems — after a likely exposure. Give adrenaline. Don't wait for a rash. Don't reach for an antihistamine.

⚠️ Alma's grandmother had never seen it before. That's the failure this rehearsal prevents.

Step 3 — Count the social costs, honestly.

⚠️ These are outcomes. They belong in the conversation and they are almost never asked about.

Step 4 — If you're considering immunotherapy, get these four answers:

⚠️ Is the goal desensitization or tolerance? (It's desensitization.) What changes about avoidance, devices and labels? (Nothing.) ⚠️ What is the reaction rate during treatment? ⚠️ What happens if we stop, or miss doses?

Step 5 — And ask the person whose allergy it is what they want out of it.

⚠️ Alma asked whether she could go to Priya's house. The adults had been talking about thresholds.